ENANTA PHARMACEUTICALS, INC (ENTA) Net income 2017–2026
ENANTA PHARMACEUTICALS, INC (ENTA) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$81.9MFY2026 · since FY2017: $21.7M → -$81.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$81.9M | +29.4% |
| FY2025 | -$116.0M | +13.3% |
| FY2024 | -$133.8M | -9.9% |
| FY2023 | -$121.8M | -54.1% |
| FY2022 | -$79.0M | -118.4% |
| FY2021 | -$36.2M | -178.0% |
| FY2020 | $46.4M | -35.5% |
| FY2019 | $72.0M | +306.3% |
| FY2018 | $17.7M | -18.3% |
| FY2017 | $21.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ENTA financial trends
ENTA RevenueENTA Net marginENTA Gross profitENTA Gross marginENTA Operating incomeENTA Operating marginENTA Operating cash flowENTA Free cash flowENTA Capital expendituresENTA Return on equityENTA Stock buybacksENTA Dividends paidENTA Total assetsENTA Total liabilitiesENTA Shareholders’ equityENTA overview →